NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $98.04 +0.40 (+0.41 %) (As of 05/26/2019 02:01 PM ET)Previous Close$98.04Today's Range$96.68 - $98.2752-Week Range$78.95 - $116.49Volume866,325 shsAverage Volume1.27 million shsMarket Capitalization$13.17 billionP/E Ratio15.54Dividend Yield2.17%Beta0.92 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Receive DGX News and Ratings via Email Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:DGX Previous Symbol CUSIP74834L10 CIK1022079 Webhttp://www.questdiagnostics.com/ Phone973-520-2700Debt Debt-to-Equity Ratio0.59 Current Ratio0.78 Quick Ratio0.74Price-To-Earnings Trailing P/E Ratio15.54 Forward P/E Ratio15.13 P/E Growth2.25 Sales & Book Value Annual Sales$7.53 billion Price / Sales1.75 Cash Flow$8.1564 per share Price / Cash Flow12.02 Book Value$39.75 per share Price / Book2.47Profitability EPS (Most Recent Fiscal Year)$6.31 Net Income$736 million Net Margins9.59% Return on Equity14.99% Return on Assets7.13%Miscellaneous Employees46,000 Outstanding Shares134,375,000Market Cap$13.17 billion Next Earnings Date7/23/2019 (Estimated) OptionableOptionable Quest Diagnostics (NYSE:DGX) Frequently Asked Questions What is Quest Diagnostics' stock symbol? Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics? Quest Diagnostics declared a quarterly dividend on Tuesday, May 14th. Stockholders of record on Monday, July 8th will be given a dividend of $0.53 per share on Monday, July 22nd. This represents a $2.12 annualized dividend and a dividend yield of 2.16%. The ex-dividend date is Friday, July 5th. View Quest Diagnostics' Dividend History. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Inc (NYSE:DGX) released its quarterly earnings results on Tuesday, April, 23rd. The medical research company reported $1.40 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.36 by $0.04. The medical research company earned $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Quest Diagnostics had a return on equity of 14.99% and a net margin of 9.59%. The firm's revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $152.00 EPS. View Quest Diagnostics' Earnings History. When is Quest Diagnostics' next earnings date? Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, July 23rd 2019. View Earnings Estimates for Quest Diagnostics. What guidance has Quest Diagnostics issued on next quarter's earnings? Quest Diagnostics updated its FY 2019 earnings guidance on Tuesday, April, 23rd. The company provided earnings per share (EPS) guidance of $6.40 for the period, compared to the Thomson Reuters consensus estimate of $6.45. The company issued revenue guidance of $7.6-7.75 billion, compared to the consensus revenue estimate of $7.68 billion. What price target have analysts set for DGX? 19 brokers have issued twelve-month target prices for Quest Diagnostics' shares. Their predictions range from $90.00 to $114.00. On average, they expect Quest Diagnostics' share price to reach $102.1250 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for Quest Diagnostics. What is the consensus analysts' recommendation for Quest Diagnostics? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Quest Diagnostics. What are Wall Street analysts saying about Quest Diagnostics stock? Here are some recent quotes from research analysts about Quest Diagnostics stock: 1. According to Zacks Investment Research, "Quest Diagnostics exited first-quarter 2019 with better-than-expected earnings and revenues.Although Diagnostic information service revenues registered a very nominal rise, after several quarters of decline, this top-line growth can be treated as a notable rebound. The company is refocusing on its diagnostic information services wing and disciplined capital deployment. Its acquisitions and collaborations with hospitals continue to act as key drivers. We are upbeat about Quest Diagnostics’ Preferred Network partnership with UnitedHealthcare. On the flip side, the company is currently facing several reimbursement issues. Also, a rise in patient concession along with certain reserve adjustments caused a decline in revenue per requisition. Also, adjusted earnings declined on a year-over-year basis. This apart, escalating costs and a tough competitive landscape are concerns. In the past three months, the company has outperformed its industry." (5/13/2019) 2. Canaccord Genuity analysts commented, "We have written before that large labs (LH, DGX) and most of the rest of the non- specialized lab industry will face major challenges in 2019 and beyond. That said, we believe Quest is better positioned than LabCorp as Quest is a share gainer related to the UNH contract. DGX indicated that its UNH volumes build each week, and we expect DGX will drive 2-3 points of to offset the ~260bps headwind related to reimbursement. We think the 2019 bar is set appropriately and DGX likely can recover more in 2H/19. DGX is paying a 2.4% dividend yield. We maintain our BUY, trim our estimates and our PT to $97, which uses a 14.4x multiple on our ’20 Adj. EPS of $6.75. Q4/18 results. Adj. EPS of $1.36 (-3% Y/Y%) matched our/Street’s ~$1.36, while revs of $1,839M (-1.4% Y/Y) missed our/Street’s ~$1,878M (+0.7%). Rev./req." (2/18/2019) 3. Barclays PLC analysts commented, "We were surprised there was another leg down in the quarter, though one silver lining is that volume growth of 3.4% appears improved – and the company noted that 2019 is off to a good start. $1.36 was modestly better than our forecast of $1.35. Additionally, Quest had an active 4Q18 of capital deployment, repurchasing $175mm of stock, $200mm towards acquisitions, and $68mm toward dividends. Ultimately, shares now trade at 13x our new 2019 EPS forecast of $6.40, and we believe sentiment is near a trough despite the potential for leverageable share gains in 2019. In our view, structural trends should be at the back of the national labs to consolidate testing share – and this is Quest’s time to shine." (2/15/2019) Has Quest Diagnostics been receiving favorable news coverage? News stories about DGX stock have trended negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Quest Diagnostics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next several days. Who are some of Quest Diagnostics' key competitors? Some companies that are related to Quest Diagnostics include Laboratory Corp. of America (LH), Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Psychemedics (PMD). What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Honeywell International (HON), Micron Technology (MU), United Rentals (URI), Accenture (ACN) and AutoZone (AZO). Who are Quest Diagnostics' key executives? Quest Diagnostics' management team includes the folowing people: Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44) Who are Quest Diagnostics' major shareholders? Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.09%), Macquarie Group Ltd. (6.00%), American Century Companies Inc. (3.69%), Boston Partners (2.26%), Victory Capital Management Inc. (2.12%) and Geode Capital Management LLC (1.63%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics. Which major investors are selling Quest Diagnostics stock? DGX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Robeco Institutional Asset Management B.V., State of Tennessee Treasury Department, Acadian Asset Management LLC, American Century Companies Inc., Teacher Retirement System of Texas, Skandinaviska Enskilda Banken AB publ and Marshall Wace LLP. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Jeffrey M Leiden and Michael E Prevoznik. View Insider Buying and Selling for Quest Diagnostics. Which major investors are buying Quest Diagnostics stock? DGX stock was acquired by a variety of institutional investors in the last quarter, including Boston Partners, Amundi Pioneer Asset Management Inc., FMR LLC, BlackRock Inc., Macquarie Group Ltd., Janus Henderson Group PLC, Retirement Systems of Alabama and First Trust Advisors LP. View Insider Buying and Selling for Quest Diagnostics. How do I buy shares of Quest Diagnostics? Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quest Diagnostics' stock price today? One share of DGX stock can currently be purchased for approximately $98.04. How big of a company is Quest Diagnostics? Quest Diagnostics has a market capitalization of $13.17 billion and generates $7.53 billion in revenue each year. The medical research company earns $736 million in net income (profit) each year or $6.31 on an earnings per share basis. Quest Diagnostics employs 46,000 workers across the globe. What is Quest Diagnostics' official website? The official website for Quest Diagnostics is http://www.questdiagnostics.com/. How can I contact Quest Diagnostics? Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected] MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)Community Ranking: 1.8 out of 5 ()Outperform Votes: 393 (Vote Outperform)Underperform Votes: 715 (Vote Underperform)Total Votes: 1,108MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.